UsAgainstAlzheimer's

Washington, DC, July 06, 2023 (GLOBE NEWSWIRE) -- Patient advocacy organization UsAgainstAlzheimer’s today hailed the first-of-its-kind traditional approval by the Food and Drug Administration (FDA) of lecanemab (marketed as Leqembi), a…

<!-- Name:DistributionId Value:8823996 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

Washington, D.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- During UsAgainstAlzheimer’s 2022 National Summit, members of Congress, scientists, and other leaders spoke out against the Centers for Medicare and Medicaid Services (CMS) decision to…

Washington, DC, Oct. 12, 2022 (GLOBE NEWSWIRE) -- With the federal government’s decision to deny Medicare coverage of an entire class of Alzheimer’s treatments, as well as the promising clinical trial data regarding lecanemab released…

Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS) about last week’s National Coverage Determination…